• Publications
  • Influence
Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.
The role of rituximab, a chimeric monoclonal antibody directed against the CD20 antigen, in the treatment of patients with chronic idiopathic thrombocytopenic purpura (ITP) has not been determined.Expand
  • 537
  • 16
  • PDF
Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura.
PURPOSE To define response to therapy and ultimate outcome of adults with idiopathic thrombocytopenic purpura (ITP). PATIENTS AND METHODS We retrospectively analyzed patients with ITP diagnosedExpand
  • 327
  • 15
Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab.
The effects of B-cell depletion with rituximab on regulatory T cells (Tregs) have not been determined. We investigated Tregs in patients receiving rituximab for chronic idiopathic thrombocytopenicExpand
  • 302
  • 10
Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management.
Idiopathic thrombocytopenic purpura (ITP) is characterized by a low platelet count, which is the result of both increased platelet destruction and insufficient platelet production. Although theExpand
  • 238
  • 9
  • PDF
Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura.
Rituximab, an anti-CD20 monoclonal antibody, has been used to treat autoimmune disorders such as idiopathic thrombocytopenic purpura (ITP). However, its mechanisms of action as well as the effects onExpand
  • 268
  • 8
  • PDF
Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
OBJECTIVE Rituximab, a chimeric anti-CD20 monoclonal antibody, has been shown to be quite effective in the treatment of immune disorders resulting from autoantibodies. We prospectively studied theExpand
  • 228
  • 8
  • PDF
Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura.
PURPOSE To investigate the relation between Helicobacter pylori infection and the clinical features of idiopathic thrombocytopenic purpura (ITP), and to examine the effects of H. pylori eradicationExpand
  • 91
  • 7
Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura.
In a recent issue of Blood we reported that rituximab anti-CD20 monoclonal antibody is an active drug in adults with chronic idiopathic thrombocytopenic purpura (ITP), that it is able to induceExpand
  • 122
  • 6
  • PDF
Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia.
The activity and safety profile of selective B-cell depletion with rituximab, an anti-CD20 monoclonal antibody, were evaluated in 10 patients with acquired hemophilia. Rituximab was givenExpand
  • 204
  • 5
  • PDF
Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura.
Antibodies against phospholipid antigens (APA) have been demonstrated in idiopathic thrombocytopenic purpura (ITP), but their clinical and pathogenetic significance has remained elusive. In thisExpand
  • 147
  • 3
  • PDF